Last reviewed · How we verify
NCT04045847
CD147-CART Cells in Patients With Recurrent Malignant Glioma.
Status unknown
EARLY_PHASE1
Last updated 7 May 2020
What this trial tests
EARLY_PHASE1 trial testing CD147-CART in Recurrent Glioblastoma in 31 participants. Status unknown.
Timeline
30 May 2019
Primary endpoint
30 October 2020
30 October 2020
30 May 2022
Quick facts
| Lead sponsor | Xijing Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 31 |
| Start date | 30 May 2019 |
| Primary completion | 30 October 2020 |
| Estimated completion | 30 May 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD147-CART — full drug profile →
Conditions studied
- Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →
- CD147 Positive — all drugs for CD147 Positive →
Sponsor
Xijing Hospital
Who can join
Adults 18 to 65, any sex, with Recurrent Glioblastoma or CD147 Positive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, single-arm, open label and dose escalation clinical study of anti-CD147 CART cells in patients with recurrent malignant glioma.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.
Wu W, Klockow JL, Zhang M, Lafortune F, et al · · 2021 · cited 532× · PMID 34302977 · DOI 10.1016/j.phrs.2021.105780 -
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H, Liu C, Hu A, Zhang D, et al · · 2024 · cited 232× · PMID 38720342 · DOI 10.1186/s13045-024-01544-7 -
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
Dagar G, Gupta A, Masoodi T, Nisar S, et al · · 2023 · cited 130× · PMID 37420216 · DOI 10.1186/s12967-023-04292-3 -
CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma.
Maggs L, Cattaneo G, Dal AE, Moghaddam AS, et al · · 2021 · cited 113× · PMID 34113233 · DOI 10.3389/fnins.2021.662064 -
Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Pearson JRD, Cuzzubbo S, McArthur S, Durrant LG, et al · · 2020 · cited 92× · PMID 33178210 · DOI 10.3389/fimmu.2020.582106 -
CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
Lin YJ, Mashouf LA, Lim M. · · 2022 · cited 83× · PMID 35265074 · DOI 10.3389/fimmu.2022.817296 -
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Hosseinkhani N, Derakhshani A, Kooshkaki O, Abdoli Shadbad M, et al · · 2020 · cited 83× · PMID 33167514 · DOI 10.3390/ijms21218305 -
Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies.
Dannenfelser R, Allen GM, VanderSluis B, Koegel AK, et al · · 2020 · cited 78× · PMID 32916097 · DOI 10.1016/j.cels.2020.08.002
Verify or expand the search:
- PubMed search for NCT04045847
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CD147-CART
Trials testing the same drug.
- NCT03993743 — A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma · Phase 1 · unknown
Other recruiting trials for Recurrent Glioblastoma
Currently open trials in the same condition.
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07209241 — Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM · Phase 1 · recruiting
- NCT06910306 — Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma · NA · recruiting
- NCT07193628 — B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma · Phase 1 · recruiting
- NCT07076472 — Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of P · EARLY_PHASE1 · recruiting
Other Xijing Hospital trials
Trials by the same sponsor.
- NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
- NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
- NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
- NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04045847 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
- Last refreshed: 7 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04045847.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing